4.25

0.93% -0.04

2seventy bio Inc (TSVT)

Overview News Price History Option Chain Why TSVT Down? Discussions Forecast

2seventy bio Inc stock is currently priced at $4.25, with a 24-hour trading volume of 254.90K. It has seen a -0.93% decreased in the last 24 hours and a -14.31% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $4.03 pivot point. If it approaches the $4.61 resistance level, significant changes may occur.

Previous Close:

$4.29

Open:

$4.25

24h Volume:

254.90K

Market Cap:

$216.91M

Revenue:

$100.39M

Net Income/Loss:

$-217.57M

P/E Ratio:

-1.0291

EPS:

-4.13

Net Cash Flow:

$-180.72M

1W Performance:

-5.97%

1M Performance:

-14.31%

6M Performance:

+66.67%

1Y Performance:

-49.70%

1D Range:

$4.135

$4.3788

52W Range:

$1.535

$12.69

2seventy bio Inc Stock (TSVT) Company Profile

Name

2seventy bio Inc

Sector

Healthcare (1203)

Industry

Biotechnology (688)

Phone

339-499-9300

Address

60 Binney Street, Cambridge

Employee

Twitter

Next Earnings Date

2024-05-01

Latest SEC Filings

TSVT's Discussions on Twitter

2seventy bio Inc Stock (TSVT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-13-23	Downgrade	Goldman	Buy → Neutral
Sep-12-23	Downgrade	Guggenheim	Buy → Neutral
Jul-28-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Oct-31-22	Initiated	Guggenheim	Buy
May-02-22	Initiated	Goldman	Buy
Feb-10-22	Initiated	SVB Leerink	Outperform
Jan-06-22	Initiated	Cowen	Outperform
Nov-09-21	Initiated	Canaccord Genuity	Buy
Nov-08-21	Initiated	Morgan Stanley	Overweight
Nov-08-21	Initiated	Wedbush	Outperform

View All

2seventy bio Inc Stock (TSVT) Latest News

Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know

Zacks Investment Research

2seventy bio, Inc. (TSVT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks Investment Research

2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why

Zacks Investment Research

The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals

Zacks Investment Research

Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Abecma

Zacks Investment Research

FDA Expands J&J's (JNJ) Carvykti Label in Multiple Myeloma

Zacks Investment Research

2seventy bio Inc Stock (TSVT) Financials Data

2seventy bio Inc (TSVT) Revenue 2024

TSVT reported a revenue (TTM) of $100.39 million for the quarter ending December 31, 2023, a +9.72% rise year-over-year.

2seventy bio Inc (TSVT) Net Income 2024

TSVT net income (TTM) was -$217.57 million for the quarter ending December 31, 2023, a +14.39% increase year-over-year.

2seventy bio Inc (TSVT) Cash Flow 2024

TSVT recorded a free cash flow (TTM) of -$180.72 million for the quarter ending December 31, 2023, a +30.21% increase year-over-year.

2seventy bio Inc (TSVT) Earnings per Share 2024

TSVT earnings per share (TTM) was -$4.42 for the quarter ending December 31, 2023, a +40.59% growth year-over-year.

2seventy bio Inc Stock (TSVT) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Casdin Capital, LLC	Director	Mar 25 '24	Buy	5.07	330,000	1,673,991	1,960,000
Casdin Capital, LLC	Director	Mar 22 '24	Buy	5.12	147,377	754,069	1,630,000
Casdin Capital, LLC	Director	Mar 21 '24	Buy	4.90	300,000	1,470,990	1,482,623
Leschly Nick	President and CEO	Jan 05 '24	Sale	3.75	1,554	5,833	1,085,476
Baird William D III	Chief Operating Officer	Jan 05 '24	Sale	3.75	1,380	5,180	161,335
Gregory Philip D	Chief Scientific Officer	Jan 05 '24	Sale	3.75	795	2,984	230,842
Leschly Nick	President and CEO	Jan 03 '24	Sale	3.87	72,312	279,739	1,087,030
Baird William D III	Chief Operating Officer	Jan 03 '24	Sale	3.87	33,651	130,179	162,715
Gregory Philip D	Chief Scientific Officer	Jan 03 '24	Sale	3.87	25,613	99,084	231,637
Leschly Nick	President and CEO	Aug 22 '23	Sale	5.49	9,312	51,090	1,159,342

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts. 2seventy bio, Inc.(NasdaqGS:TSVT.V) operates independently of bluebird bio, Inc. as of November 4, 2021.